Figure 2.
![EFS and OS following lenalidomide remission induction therapy vs control induction treatment. EFS (A) and OS (B) for patients receiving remission induction therapy (control group vs lenalidomide [Lena] therapy group). Patients were randomly assigned for their first and second induction cycles of combination chemotherapy without additional lenalidomide (control treatment) or with lenalidomide at 15 mg on days 1 to 21 of both cycles. F, failure (or event).](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/5/4/10.1182_bloodadvances.2020003855/1/advancesadv2020003855f2.png?Expires=1735804334&Signature=ZUwrw-jUF6SDHNMWepWFKLubrBCijhscHliTN4uOG9-eAsduPT1WXrsvZ6AgimBXniQ6tipWdoBXZqP8BvkcznzJFq6aoqwR9AtxNLj8SteiADUeN6utLd3fQqZXBA6biYlMfQ1fnK2suyxiFw8hgrdM8Cb7qh2PaK1l3fHyW~4MRx2fBBFrbfoCRgwyOds2hskE7JM2gtQK37FNhOB0PYud62P~OK25pNJmtx6Ckv48xK7LchtvdLZS9kNuOQCgVmOo7mEaPrFJkpIh1vLONWnKEa-cS5hZ0HXJCrKNomNrKz~mr1P-5FrSk5792K5pVJeRpOxZAtDDQu0CucZh-g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
EFS and OS following lenalidomide remission induction therapy vs control induction treatment. EFS (A) and OS (B) for patients receiving remission induction therapy (control group vs lenalidomide [Lena] therapy group). Patients were randomly assigned for their first and second induction cycles of combination chemotherapy without additional lenalidomide (control treatment) or with lenalidomide at 15 mg on days 1 to 21 of both cycles. F, failure (or event).